Expert consensus on safety management of bone-modifying agents.
10.3760/cma.j.cn112152-20210413-00312
- Collective Name:Breast Cancer Group, Chinese Medical Doctor Association;International Medical Society, Chinese Anti-cancer Association
- Publication Type:Journal Article
- Keywords:
Adverse event;
Bone metastasis;
Bone-modifying agent;
Expert consensus;
Malignant tumor
- MeSH:
Bone Density Conservation Agents/adverse effects*;
Consensus;
Diphosphonates/adverse effects*;
Humans;
Osteoporosis/drug therapy*;
Quality of Life;
Safety Management
- From:
Chinese Journal of Oncology
2021;43(6):622-628
- CountryChina
- Language:Chinese
-
Abstract:
Bone-modifying agents currently include bisphosphonates and desumumab, which are the main drugs for the treatment of malignant tumor bone metastasis, hypercalcemia and osteoporosis. Due to its wide clinical application, the adverse events of this kind of drugs are gradually increasing and affecting the quality of life of patients. Therefore, it needs to arouse the attention of the majority of medical personnel. Based on the substantial evidence, the expert committee has thoroughly discussed the management of adverse reactions of bone modifying agents and put forward reasonable suggestions, to guide clinicians in the safety management of such drugs.
